MESA, AZ–(Marketwired – Apr 10, 2014) –Ulthera, Inc., a global medical device company focused on developing and commercializing technologies for aesthetic and medical applications, announced today that Marshall L. Mohr has joined its board of directors.Continue reading
Author Archive: AZBio
Patrick Roche, Ph.D., Joins HTG Molecular Diagnostics
TUCSON, Ariz. (April 9, 2014) HTG Molecular Diagnostics, Inc., (HTG) today announced that Patrick Roche, Ph.D., has joined the company as Sr. Vice President for IVD Assay Development.Continue reading
AZBio CEO Makes the Case for Medical Innovation Investments in the Arizona Capitol Times
Saving money, improving lives – investing in medical innovation is a smart budget decisionContinue reading
PhRMA Report Looks at Alternate Growth Scenarios
New Report Reveals Growth Trajectories and Top Policy Factors Affecting Biopharmaceutical Innovation & Growth. New analysis incorporates real world insights from industry leadersContinue reading
Pfizer’s Ian Read succeeds Celgene’s Bob Hugin as PhRMA Board Chair
Pfizer’s Ian Read Becomes PhRMA Board Chairman; Ken Frazier, George Scangos Assume New PostsContinue reading
BioPharm Insight: Regenesis now sees exit as sale to strategic player in 12 to 24 months – CEO
Regenesis Biomedical, a Scottsdale, Arizona-based medical device company, now sees a sale to a strategic in 2015 or 2016 as its likely exit, said CEO Scott Brooks.Continue reading
Capstone Therapeutics Announces Initiation of Dosing for AEM-28 Phase 1 Human Clinical Trial in LDL/non-HDL Cholesterol Reduction
Capstone Therapeutics (OTCQB:CAPS) (“the Company”) and its joint venture affiliate, LipimetiX Development, LLC (“JV”), announced today the initiation of dosing for its AEM-28 (Apo E mimetic peptide) Phase 1 human clinical trial in LDL/non-HDL cholesterol reduction.Continue reading
Arizona’s Bioscience Roadmap: 2014-2025 Unveiled
PHOENIX—The strategic plan that has guided Arizona’s fast-growing bioscience sector for nearly 12 years is gearing up for a new decade.Continue reading
HTG Molecular Diagnostics and OvaGene Oncology Partner on Gynecologic Cancer Tests
TUCSON, AZ–(Marketwired – Apr 7, 2014) – HTG Molecular Diagnostics, Inc., (HTG) and OvaGene Oncology have entered a manufacturing supply agreement where OvaGene will design and develop their proprietary gene expression assays on HTG’s fully automated, extraction-free Edge Platform.Continue reading
IMS Health Goes Public – IPO Raises $1.3 Billion
The IMS Health Holdings (NYSE:IMS) IPO represents the second-biggest IPO so far this year in the U.S.
IMS Heath’s IMS One portfolio of products includes 360 Vantage|IMS Health (Chandler, AZ). 360 Vantage was acquired by IMS Heath in May of 2013.